D Koutsimpelas1, G Ruerup, W J Mann, J Brieger. 1. Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz, Germany. koutsimpelas@hno.klinik.uni-mainz.de
Abstract
BACKGROUND: Vestibular schwannomas (VS) are benign tumors of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). In VS, losses of chromosomal material and mutations of the NF2 gene have been established to be causative. For a subset of VS without detectable gene alterations, promoter inactivation by hypermethylation has been suggested. However, published data are very limited and contradictory. METHODS: We analyzed NF2 gene promoter methylation in 35 sporadic VS by methylation-specific PCR. RESULTS: Twenty-three of the tumors were informative, showing no promoter methylation. In the remaining 12 tumors, promoter methylation could neither be verified nor excluded. CONCLUSIONS: Our study suggests that NF2 gene inactivation by promoter hypermethylation is a rare or very uncommon mechanism of NF2 gene inactivation in sporadic VS. Other mechanisms destabilizing the NF2 gene product, yet to be identified, might play a role in the genesis of VS apart from the loss or mutation of the NF2 gene.
BACKGROUND:Vestibular schwannomas (VS) are benign tumors of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). In VS, losses of chromosomal material and mutations of the NF2 gene have been established to be causative. For a subset of VS without detectable gene alterations, promoter inactivation by hypermethylation has been suggested. However, published data are very limited and contradictory. METHODS: We analyzed NF2 gene promoter methylation in 35 sporadic VS by methylation-specific PCR. RESULTS: Twenty-three of the tumors were informative, showing no promoter methylation. In the remaining 12 tumors, promoter methylation could neither be verified nor excluded. CONCLUSIONS: Our study suggests that NF2 gene inactivation by promoter hypermethylation is a rare or very uncommon mechanism of NF2 gene inactivation in sporadic VS. Other mechanisms destabilizing the NF2 gene product, yet to be identified, might play a role in the genesis of VS apart from the loss or mutation of the NF2 gene.
Authors: Miguel Torres-Martin; Luis Lassaletta; Alberto Isla; Jose M De Campos; Giovanny R Pinto; Rommel R Burbano; Javier S Castresana; Barbara Melendez; Juan A Rey Journal: Oncol Rep Date: 2014-10-03 Impact factor: 3.906
Authors: Miguel Torres-Martin; Luis Lassaletta; Jose M de Campos; Alberto Isla; Javier Gavilan; Giovanny R Pinto; Rommel R Burbano; Farida Latif; Barbara Melendez; Javier S Castresana; Juan A Rey Journal: PLoS One Date: 2013-06-11 Impact factor: 3.240
Authors: Miguel Torres-Martin; Luis Lassaletta; Jesus San-Roman-Montero; Jose M De Campos; Alberto Isla; Javier Gavilan; Barbara Melendez; Giovanny R Pinto; Rommel R Burbano; Javier S Castresana; Juan A Rey Journal: Int J Oncol Date: 2013-01-24 Impact factor: 5.650
Authors: Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu Journal: Otol Neurotol Date: 2020-06 Impact factor: 2.619